Supernus Pharmaceuticals (SUPN) reported $207.71 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 38.6%. EPS of $0.59 for the same period compares to $0.42 a year ago.
The reported revenue represents a surprise of +10.22% over the Zacks Consensus Estimate of $188.45 million. With the consensus EPS estimate being $0.28, the EPS surprise was +110.71%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Supernus performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Revenues- Net product sales- Trokendi XR: $9.48 million versus the two-analyst average estimate of $6.35 million. The reported number represents a year-over-year change of -26%.
- Revenues- Net product sales- Oxtellar XR: $7.42 million versus $5.93 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -27.2% change.
- Revenues- Net product sales- APOKYN: $7.73 million compared to the $9.19 million average estimate based on two analysts. The reported number represents a change of -48.5% year over year.
- Revenues- Net product sales- Qelbree: $77.84 million versus the two-analyst average estimate of $80.06 million. The reported number represents a year-over-year change of +20.3%.
- Revenues- Collaboration revenue (ZURZUVAE): $27.64 million versus the two-analyst average estimate of $31.33 million.
- Revenues- Net product sales: $150.75 million compared to the $152.45 million average estimate based on two analysts. The reported number represents a change of +6.2% year over year.
- Revenues- Royalty, licensing and other revenues: $29.31 million versus the two-analyst average estimate of $2.5 million. The reported number represents a year-over-year change of +274%.
- Revenues- Net Product Sales- ONAPGO: $8.38 million compared to the $10.26 million average estimate based on two analysts.
- Revenues- Net product sales- GOCOVRI: $35.24 million compared to the $35.3 million average estimate based on two analysts. The reported number represents a change of +14.8% year over year.
View all Key Company Metrics for Supernus here>>>
Shares of Supernus have returned -3.8% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpSupernus Pharmaceuticals, Inc. (SUPN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
